Cargando…

Therapeutic approaches for SARS-CoV-2 infection

Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Ankur, Pradhan, Anish, Maurya, Vimal K., Kumar, Swatantra, Theengh, Angila, Puri, Bipin, Saxena, Shailendra K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096528/
https://www.ncbi.nlm.nih.gov/pubmed/33962011
http://dx.doi.org/10.1016/j.ymeth.2021.04.026
_version_ 1783688178213847040
author Gupta, Ankur
Pradhan, Anish
Maurya, Vimal K.
Kumar, Swatantra
Theengh, Angila
Puri, Bipin
Saxena, Shailendra K.
author_facet Gupta, Ankur
Pradhan, Anish
Maurya, Vimal K.
Kumar, Swatantra
Theengh, Angila
Puri, Bipin
Saxena, Shailendra K.
author_sort Gupta, Ankur
collection PubMed
description Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients based on host’s nutritional, metabolic, and lifestyle status. Further, complementary and alternative medicine (CAM) approaches have also improved resiliency and immune responses. In this article, we summarize all the therapeutic antiviral strategies for COVID-19 drug discovery including computer aided virtual screening, repurposed drugs, immunomodulators, vaccines, plasma therapy, various adjunct therapies, and phage technology to unravel insightful mechanistic pathways of targeting SARS-CoV-2 and host’s intrinsic, innate immunity at multiple checkpoints that aid in the containment of the disease.
format Online
Article
Text
id pubmed-8096528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-80965282021-05-05 Therapeutic approaches for SARS-CoV-2 infection Gupta, Ankur Pradhan, Anish Maurya, Vimal K. Kumar, Swatantra Theengh, Angila Puri, Bipin Saxena, Shailendra K. Methods Article Therapeutic approaches to COVID-19 treatment require appropriate inhibitors to target crucial proteins of SARS-CoV-2 replication machinery. It’s been approximately 12 months since the pandemic started, yet no known specific drugs are available. However, research progresses with time in terms of high throughput virtual screening (HTVS) and rational design of repurposed, novel synthetic and natural products discovery by understanding the viral life cycle, immuno-pathological and clinical outcomes in patients based on host’s nutritional, metabolic, and lifestyle status. Further, complementary and alternative medicine (CAM) approaches have also improved resiliency and immune responses. In this article, we summarize all the therapeutic antiviral strategies for COVID-19 drug discovery including computer aided virtual screening, repurposed drugs, immunomodulators, vaccines, plasma therapy, various adjunct therapies, and phage technology to unravel insightful mechanistic pathways of targeting SARS-CoV-2 and host’s intrinsic, innate immunity at multiple checkpoints that aid in the containment of the disease. Elsevier Inc. 2021-11 2021-05-05 /pmc/articles/PMC8096528/ /pubmed/33962011 http://dx.doi.org/10.1016/j.ymeth.2021.04.026 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Gupta, Ankur
Pradhan, Anish
Maurya, Vimal K.
Kumar, Swatantra
Theengh, Angila
Puri, Bipin
Saxena, Shailendra K.
Therapeutic approaches for SARS-CoV-2 infection
title Therapeutic approaches for SARS-CoV-2 infection
title_full Therapeutic approaches for SARS-CoV-2 infection
title_fullStr Therapeutic approaches for SARS-CoV-2 infection
title_full_unstemmed Therapeutic approaches for SARS-CoV-2 infection
title_short Therapeutic approaches for SARS-CoV-2 infection
title_sort therapeutic approaches for sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096528/
https://www.ncbi.nlm.nih.gov/pubmed/33962011
http://dx.doi.org/10.1016/j.ymeth.2021.04.026
work_keys_str_mv AT guptaankur therapeuticapproachesforsarscov2infection
AT pradhananish therapeuticapproachesforsarscov2infection
AT mauryavimalk therapeuticapproachesforsarscov2infection
AT kumarswatantra therapeuticapproachesforsarscov2infection
AT theenghangila therapeuticapproachesforsarscov2infection
AT puribipin therapeuticapproachesforsarscov2infection
AT saxenashailendrak therapeuticapproachesforsarscov2infection